Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	46.35	39.55	298.17	89.96	81.47	58.06
Short-Term Investments	49.73	62.88	29.31	83.51	211.47	222.77
Cash & Short-Term Investments	96.08	102.43	327.48	173.47	292.94	280.83
Cash Growth	-42.62%	-68.72%	88.79%	-40.79%	4.31%	-44.42%
Accounts Receivable	14.3	17.47	16.79	14.07	15.87	22
Other Receivables	-	-	-	-	53.8	28.57
Receivables	14.3	17.47	16.79	14.07	69.67	50.57
Prepaid Expenses	8.93	13.64	9.2	18.81	30.73	7.09
Other Current Assets	-	-	-	43.53	-	-
Total Current Assets	119.31	133.54	353.46	249.87	393.34	338.49
Property, Plant & Equipment	39.96	45.36	52	53.35	59.68	59.25
Long-Term Investments	-	-	-	-	12.75	4.99
Other Long-Term Assets	202.77	203.1	201.94	71.6	3.28	6.11
Total Assets	362.03	382	607.4	374.82	469.06	408.83
Accounts Payable	1.67	1.52	1.55	3.1	6.78	4.76
Accrued Expenses	10.56	12.83	20.41	37.95	76.07	57.76
Current Portion of Long-Term Debt	-	-	-	16.94	19.33	9.85
Current Portion of Leases	4.22	3.92	6.75	0.5	9.87	7.76
Current Unearned Revenue	-	-	-	0.1	11.52	31.58
Other Current Liabilities	6.49	6.49	-	-	-	-
Total Current Liabilities	22.95	24.77	28.72	58.59	123.57	111.7
Long-Term Debt	-	-	-	599.39	599.84	445.19
Long-Term Leases	42.44	45.24	45.41	52.68	47.22	47.73
Long-Term Unearned Revenue	-	-	0.19	0.31	0.35	6.76
Other Long-Term Liabilities	102.95	99	91.29	2.42	1.83	21.29
Total Liabilities	168.34	169	165.6	713.39	772.81	632.67
Common Stock	-	-	0	0	0	0
Additional Paid-In Capital	1,131	1,122	1,296	1,387	1,223	1,025
Retained Earnings	-937.3	-909.1	-853.91	-1,726	-1,527	-1,249
Comprehensive Income & Other	-0.02	-0.07	-0.02	-	0.05	0.15
Shareholders' Equity	193.69	213	441.8	-338.57	-303.75	-223.84
Total Liabilities & Equity	362.03	382	607.4	374.82	469.06	408.83
Total Debt	46.66	49.16	52.16	669.52	676.26	510.53
Net Cash (Debt)	49.42	53.27	275.32	-496.05	-383.32	-224.71
Net Cash Growth	-57.31%	-80.65%	-	-	-	-
Net Cash Per Share	1.00	0.96	3.74	-7.14	-6.15	-4.04
Filing Date Shares Outstanding	48.92	48.16	62.86	74.7	64.33	62.52
Total Common Shares Outstanding	48.92	48.09	65.23	74.44	64.33	57.02
Working Capital	96.36	108.77	324.75	191.28	269.77	226.79
Book Value Per Share	3.96	4.43	6.77	-4.55	-4.72	-3.93
Tangible Book Value	193.69	213	441.8	-338.57	-303.75	-223.84
Tangible Book Value Per Share	3.96	4.43	6.77	-4.55	-4.72	-3.93
Machinery	-	3.68	19.04	26.03	35.88	36.33
Leasehold Improvements	-	26.21	24.58	24.05	24.28	22.16

Source: S&P Capital IQ. Standard template. Financial Sources.